About the Company
We do not have any company description for Pelthos Therapeutics Inc. at the moment.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Pelthos Therapeutics Inc.
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response ...
Why Is Pelthos Therapeutics Stock Trading Higher Thursday - Pelthos ...
agreed to combine Ligand's wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos), with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel.
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly ...
Pelthos Therapeutics Inc. (NYSE:PTHS) on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for molluscum contagiosum (molluscum) in adults and pediatric patients one year of ...
PTHS - Pelthos Therapeutics Inc Executives | Morningstar
Learn about the executive team and board of directors at Pelthos Therapeutics Inc (PTHS:XASE) and review their bios and compensation over the latest fiscal years.
Pelthos Therapeutics Inc. (PTHS) Stock Price Today - WSJ
View the latest Pelthos Therapeutics Inc. (PTHS) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Pelthos Therapeutics Completes Merger with Channel Therapeutics and ...
Combined company will operate under the name “Pelthos Therapeutics Inc.” and will trade on the NYSE American exchange under the ticker symbol “PTHS” starting on July 2, 2025 ...
Pelthos Therapeutics Inc. Stock Grades | PTHS | Barron's
About Pelthos Therapeutics Inc. Channel Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of therapeutics. It focuses on non-opioid ...
Pelthos Therapeutics, Inc.: Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI ...
Pelthos Therapeutics Launches First At-Home Prescription Gel For ... - AOL
Pelthos Therapeutics Inc. (NYSE:PTHS) on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for molluscum contagiosum (molluscum) in adults and pediatric patients one year of ...
PTHS - Pelthos Therapeutics Inc Sustainability | Morningstar
Review Pelthos Therapeutics Inc (PTHS:XASE) stock and the current sustainability and ESG risk rating to help with your investing decisions.
Pelthos Therapeutics Completes Merger with Channel Therapeutics and ...
Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name “Pelthos Therapeutics Inc.” and ...
Similar Companies
Loading the latest forecasts...